Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
| Autor: | Michael R. Green, Russell L. Basser, Dora Menchaca, Elizabeth O'Flaherty, Maria Edmonds, C. Glenn Begley, Brian Cohen, Janet L. Nichol |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Myeloid
Pancytopenia Megakaryocyte Progenitor Cells Immunology Adenocarcinoma Biochemistry Colony-Stimulating Factors Megakaryocyte hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Thrombopoietin Autoantibodies Megakaryocytopoiesis Ovarian Neoplasms business.industry Recombinant Human Thrombopoietin Cell Biology Hematology Middle Aged medicine.disease Recombinant Proteins Granulocyte colony-stimulating factor medicine.anatomical_structure Female business |
| Zdroj: | Blood. 99:2599-2602 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use. We here report a case of pancytopenia associated with the development of neutralizing antibodies to TPO that occurred in a patient who had undergone multicycle chemotherapy with multiple cycles of subcutaneous administration of pegylated recombinant human megakaryocyte growth and development factor. Samples of the patient's bone marrow showed trilineage hypoplasia with absence of myeloid, erythroid, and megakaryocyte progenitor cells but with elevated endogenous levels of erythropoietin, granulocyte colony-stimulating factor, and stem-cell factor. To our knowledge, this is the first report of an aplastic anemia–like syndrome associated with neutralizing antibodies to TPO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|